59 related articles for article (PubMed ID: 16417239)
21. Checkpoint inhibitors in hematological malignancies.
Ok CY; Young KH
J Hematol Oncol; 2017 May; 10(1):103. PubMed ID: 28482851
[TBL] [Abstract][Full Text] [Related]
22. Sézary Syndrome: Clinical and Biological Aspects.
Kohnken R; Fabbro S; Hastings J; Porcu P; Mishra A
Curr Hematol Malig Rep; 2016 Dec; 11(6):468-479. PubMed ID: 27704468
[TBL] [Abstract][Full Text] [Related]
23. Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets.
Saulite I; Hoetzenecker W; Weidinger S; Cozzio A; Guenova E; Wehkamp U
Biomed Res Int; 2016; 2016():9717530. PubMed ID: 27294147
[TBL] [Abstract][Full Text] [Related]
24. Complete regression of mycosis fungoides after ipilimumab therapy for advanced melanoma.
Bar-Sela G; Bergman R
JAAD Case Rep; 2015 Mar; 1(2):99-100. PubMed ID: 27051697
[No Abstract] [Full Text] [Related]
25. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.
Herrmann A; Priceman SJ; Swiderski P; Kujawski M; Xin H; Cherryholmes GA; Zhang W; Zhang C; Lahtz C; Kowolik C; Forman SJ; Kortylewski M; Yu H
J Clin Invest; 2014 Jul; 124(7):2977-87. PubMed ID: 24892807
[TBL] [Abstract][Full Text] [Related]
26. Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation.
Chan DV; Gibson HM; Aufiero BM; Wilson AJ; Hafner MS; Mi QS; Wong HK
Genes Immun; 2014 Jan; 15(1):25-32. PubMed ID: 24173147
[TBL] [Abstract][Full Text] [Related]
27. Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma.
Willerslev-Olsen A; Krejsgaard T; Lindahl LM; Bonefeld CM; Wasik MA; Koralov SB; Geisler C; Kilian M; Iversen L; Woetmann A; Odum N
Toxins (Basel); 2013 Aug; 5(8):1402-21. PubMed ID: 23949004
[TBL] [Abstract][Full Text] [Related]
28. Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sézary syndrome.
Gibson HM; Mishra A; Chan DV; Hake TS; Porcu P; Wong HK
J Invest Dermatol; 2013 Jan; 133(1):249-57. PubMed ID: 22951729
[TBL] [Abstract][Full Text] [Related]
29. Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.
Li JY; Horwitz S; Moskowitz A; Myskowski PL; Pulitzer M; Querfeld C
Cancer Manag Res; 2012; 4():75-89. PubMed ID: 22457602
[TBL] [Abstract][Full Text] [Related]
30. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Wong HK; Mishra A; Hake T; Porcu P
Br J Haematol; 2011 Oct; 155(2):150-66. PubMed ID: 21883142
[TBL] [Abstract][Full Text] [Related]
31. Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface.
Chung JS; Shiue LH; Duvic M; Pandya A; Cruz PD; Ariizumi K
Blood; 2011 Mar; 117(12):3382-90. PubMed ID: 21252093
[TBL] [Abstract][Full Text] [Related]
32. Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma.
Capriotti E; Vonderheid EC; Thoburn CJ; Wasik MA; Bahler DW; Hess AD
Leuk Lymphoma; 2008 Jun; 49(6):1190-201. PubMed ID: 18569641
[TBL] [Abstract][Full Text] [Related]
33. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides.
Chong BF; Wilson AJ; Gibson HM; Hafner MS; Luo Y; Hedgcock CJ; Wong HK
Clin Cancer Res; 2008 Feb; 14(3):646-53. PubMed ID: 18245523
[TBL] [Abstract][Full Text] [Related]
34. Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter.
Gibson HM; Hedgcock CJ; Aufiero BM; Wilson AJ; Hafner MS; Tsokos GC; Wong HK
J Immunol; 2007 Sep; 179(6):3831-40. PubMed ID: 17785820
[TBL] [Abstract][Full Text] [Related]
35. Mycosis fungoides and sezary syndrome: an update.
Kim EJ; Lin J; Junkins-Hopkins JM; Vittorio CC; Rook AH
Curr Oncol Rep; 2006 Sep; 8(5):376-86. PubMed ID: 16901399
[TBL] [Abstract][Full Text] [Related]
36. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma.
Tiemessen MM; Mitchell TJ; Hendry L; Whittaker SJ; Taams LS; John S
J Invest Dermatol; 2006 Oct; 126(10):2217-23. PubMed ID: 16741512
[TBL] [Abstract][Full Text] [Related]
37. Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides -- cutaneous T cell lymphoma.
Wong HK; Wilson AJ; Gibson HM; Hafner MS; Hedgcock CJ; Berger CL; Edelson RL; Lim HW
J Invest Dermatol; 2006 Jan; 126(1):212-9. PubMed ID: 16417239
[TBL] [Abstract][Full Text] [Related]
38. The comparison of expression of cutaneous lymphocyte-associated antigen (CLA), and Th1- and Th2-associated antigens in mycosis fungoides and cutaneous lesions of adult T-cell leukemia/lymphoma.
Yamaguchi T; Ohshima K; Tsuchiya T; Suehuji H; Karube K; Nakayama J; Suzumiya J; Yoshino T; Kikuchi M
Eur J Dermatol; 2003; 13(6):553-9. PubMed ID: 14721775
[TBL] [Abstract][Full Text] [Related]
39. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
40. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
